Tags

Type your tag names separated by a space and hit enter

PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma.
Int J Cancer. 2012 Oct 01; 131(7):1556-68.IJ

Abstract

ERK and RSK2 drive proliferation and invasion of many cancers. Phosphoprotein enriched in astrocytes 15 (PEA15) binds ERK and RSK2 and high PEA15 levels can impair ERK- and RSK2-dependent transcription. PEA15 expression also inversely correlates with cell motility and invasiveness. We therefore tested PEA15 effects on neuroblastoma cells in vitro. We further analyzed PEA15 expression in the context of clinical and genetic features of neuroblastoma in tumor samples to determine its correlation with disease progression. Affymetrix microarray analysis was performed using 24 different neuroblastoma cell lines. Cell lines expressing low to intermediate levels of PEA15 were chosen for in vitro functional studies. The cell line results were verified by Affymetrix analysis of three different neuroblastic tumor types (total of 110 samples) PEA15 overexpression inhibited neuroblastoma migration in vitro. We verified that inhibition of motility required PEA15 interaction with its binding partners ERK and RSK2. Additionally, synthetic inhibitors of RSK2 suppressed integrin-dependent migration. PEA15 expression correlates with clinical parameters and a 25% increase in patient survival rate. The highest PEA15 levels were found in low stage, more differentiated and less metastatic neuroblastic tumors, and correlated with lack of MYCN amplification. PEA15 blocks neuroblastoma migration through inhibition of ERK/RSK2 signaling. PEA15 expression levels correlate with favorable clinical features suggesting that PEA15 limits metastatic progression of neuroblastoma. Thus, PEA15 and its partners ERK and RSK2 are potential targets for the development of new therapeutics to impede progression of minimal residual disease in patients with high-risk neuroblastoma.

Authors+Show Affiliations

Cancer Biology Program, University of Hawai'i Cancer Center, University of Hawai'i at Manoa, Honolulu, HI 96813, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

22213050

Citation

Gawecka, Joanna E., et al. "PEA15 Impairs Cell Migration and Correlates With Clinical Features Predicting Good Prognosis in Neuroblastoma." International Journal of Cancer, vol. 131, no. 7, 2012, pp. 1556-68.
Gawecka JE, Geerts D, Koster J, et al. PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. Int J Cancer. 2012;131(7):1556-68.
Gawecka, J. E., Geerts, D., Koster, J., Caliva, M. J., Sulzmaier, F. J., Opoku-Ansah, J., Wada, R. K., Bachmann, A. S., & Ramos, J. W. (2012). PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. International Journal of Cancer, 131(7), 1556-68. https://doi.org/10.1002/ijc.27415
Gawecka JE, et al. PEA15 Impairs Cell Migration and Correlates With Clinical Features Predicting Good Prognosis in Neuroblastoma. Int J Cancer. 2012 Oct 1;131(7):1556-68. PubMed PMID: 22213050.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma. AU - Gawecka,Joanna E, AU - Geerts,Dirk, AU - Koster,Jan, AU - Caliva,Maisel J, AU - Sulzmaier,Florian J, AU - Opoku-Ansah,John, AU - Wada,Randal K, AU - Bachmann,André S, AU - Ramos,Joe W, Y1 - 2012/01/31/ PY - 2011/08/11/received PY - 2011/12/09/accepted PY - 2012/1/4/entrez PY - 2012/1/4/pubmed PY - 2012/10/18/medline SP - 1556 EP - 68 JF - International journal of cancer JO - Int. J. Cancer VL - 131 IS - 7 N2 - ERK and RSK2 drive proliferation and invasion of many cancers. Phosphoprotein enriched in astrocytes 15 (PEA15) binds ERK and RSK2 and high PEA15 levels can impair ERK- and RSK2-dependent transcription. PEA15 expression also inversely correlates with cell motility and invasiveness. We therefore tested PEA15 effects on neuroblastoma cells in vitro. We further analyzed PEA15 expression in the context of clinical and genetic features of neuroblastoma in tumor samples to determine its correlation with disease progression. Affymetrix microarray analysis was performed using 24 different neuroblastoma cell lines. Cell lines expressing low to intermediate levels of PEA15 were chosen for in vitro functional studies. The cell line results were verified by Affymetrix analysis of three different neuroblastic tumor types (total of 110 samples) PEA15 overexpression inhibited neuroblastoma migration in vitro. We verified that inhibition of motility required PEA15 interaction with its binding partners ERK and RSK2. Additionally, synthetic inhibitors of RSK2 suppressed integrin-dependent migration. PEA15 expression correlates with clinical parameters and a 25% increase in patient survival rate. The highest PEA15 levels were found in low stage, more differentiated and less metastatic neuroblastic tumors, and correlated with lack of MYCN amplification. PEA15 blocks neuroblastoma migration through inhibition of ERK/RSK2 signaling. PEA15 expression levels correlate with favorable clinical features suggesting that PEA15 limits metastatic progression of neuroblastoma. Thus, PEA15 and its partners ERK and RSK2 are potential targets for the development of new therapeutics to impede progression of minimal residual disease in patients with high-risk neuroblastoma. SN - 1097-0215 UR - https://www.unboundmedicine.com/medline/citation/22213050/PEA15_impairs_cell_migration_and_correlates_with_clinical_features_predicting_good_prognosis_in_neuroblastoma_ L2 - https://doi.org/10.1002/ijc.27415 DB - PRIME DP - Unbound Medicine ER -